US SEC Filing Intelligence

New Federal Contractors — April 04, 2026

This digest covers one civilian NASA contract totaling $181,839,613 in obligations, with zero defense-related awards. The Leland Stanford Junior University received the award from NASA's Goddard Space Flight Center for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a 25-year definitive cost-no-fee R&D effort in space science/applications (PSC AR22). The neutral signal (strength 4/10, materiality 6/10) highlights a stable long-term commitment but with only $25,928,889 outlayed to date against a base + all options value of $186,336,824. Highest-conviction signal is the low pricing risk and ~$7.3 million annual revenue estimate for Stanford's space R&D. Key watch item: outlay progress and performance toward the 2027-09-30 end date, amid full and open competition history.

Significant Contract Modifications ($10M+) — April 04, 2026

NASA's $181,839,613 contract modification to The Leland Stanford Junior University represents 100% civilian agency spending (0/1 defense-related), focusing on the Goddard Space Flight Center's Solar Dynamics Observatory Heliospheric and Magnetic Imager (HMI) project. This definitive cost-no-fee award, active since 2002-10-15 through 2027-09-30, highlights long-term commitment to space science R&D under full and open competition. The neutral signal (avg strength 4/10) balances sustained funding against low outlays of $25,928,889 to date and modest annual revenue estimate of ~$7.3M. Highest-conviction signal is the durability of NASA's space applications R&D investments (PSC AR22, NAICS 541710). Key watch item: outlay progress beyond $25,928,889 and execution toward 2027-09-30 amid potential civilian budget shifts.

Contract Deobligations Alert — April 04, 2026

This Contract Deobligations Alert digest synthesizes one civilian NASA contract totaling $181,839,613 in obligations to The Leland Stanford Junior University, with a 0/1 defense-related split indicating pure civilian exposure. The dominant agency and sector theme is NASA's long-term commitment to space science/applications R&D via the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation. The highest-conviction signal is neutral (4/10 strength), reflecting low outlays of $25,928,889 against the $181,839,613 obligation on a 25-year definitive cost-no-fee contract awarded in 2002. A key risk is stalled outlay progress amid the deobligation alert context, with annual revenue estimated at ~$7.3 million but uncertain due to uneven spending. Investors in civilian space R&D should watch performance toward the 2027-09-30 end date for potential funding continuity or cuts.

Contract Option Exercises — April 04, 2026

NASA's Goddard Space Flight Center exercised options totaling $181,839,613 on a single long-term contract with The Leland Stanford Junior University, representing 100% civilian exposure with zero defense-related activity. This neutral signal (strength 4/10, materiality 6/10) reflects sustained commitment to space science R&D via the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a definitive cost-no-fee award under full and open competition running through September 30, 2027. Only $25,928,889 has been outlayed to date out of a base + all options value of $186,336,824, implying an estimated annual revenue of ~$7.3 million amid uneven spending. The highest-conviction signal is the low pricing risk from the cost-no-fee structure, providing durability outside CR/NDAA volatility. Key watch item: outlay progress beyond $25.9 million and performance toward the 2027 end date.

Mega Contracts Monitor ($100M+) — April 04, 2026

A single mega contract totaling $181,839,613 in obligations was analyzed for the period April 04, 2026 to April 04, 2026, representing 100% civilian exposure (0/1 defense-related) dominated by NASA's Goddard Space Flight Center. The Leland Stanford Junior University received this definitive cost-no-fee award in 2002 for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, spanning 25 years to 2027-09-30 with only $25,928,889 outlayed to date out of a $186,336,824 base + options value. The highest-conviction signal is neutral (4/10 strength, 6/10 materiality), reflecting long-term space R&D stability tempered by slow outlay progress under full and open competition. Dominant sector theme is civilian space science/applications R&D (PSC AR22, NAICS 541710). Key risk/watch item: monitor outlay progression beyond $25,928,889 and performance toward the 2027-09-30 end date amid cost-no-fee structure.

High-Value Federal Grants ($5M+) — April 04, 2026

This digest covers a single high-value federal grant totaling $181,839,613 in obligations, entirely civilian (NASA) with zero defense-related contracts. The dominant agency is NASA via Goddard Space Flight Center, funding The Leland Stanford Junior University's Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation. The highest-conviction signal is neutral (4/10 strength), reflecting a long-term (25-year) cost-no-fee R&D commitment in space science/applications under full and open competition. Only $25,928,889 has been outlayed to date against a base + all options value of $186,336,824, implying an annual revenue estimate of ~$7.3 million. Key risk/watch item: outlay progress beyond current levels and performance toward the 2027-09-30 end date amid low pricing risk.

General Federal Contracts — April 04, 2026

NASA's Goddard Space Flight Center has obligated $181,839,613 to The Leland Stanford Junior University for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, representing 100% of the period's aggregate value with zero defense-related contracts. This single civilian award underscores a long-term commitment to space science R&D under a definitive cost-no-fee structure awarded in 2002 and extending to 2027-09-30. The highest-conviction signal is neutral (4/10 strength), reflecting steady multi-decade funding despite only $25,928,889 outlayed to date against a base + options value of $186,336,824. Full and open competition signals no immediate moat concerns, with low pricing risk. A key watch item is outlay progress and performance milestones toward the 2027 end date amid potential uneven R&D spending.

All NASA Contracts — April 04, 2026

NASA's single contract obligation of $181,839,613 during April 04, 2026, to April 04, 2026, is fully civilian with zero defense-related awards, centered on Goddard Space Flight Center's long-term space science R&D funding. The Leland Stanford Junior University received the entirety for the Solar Dynamics Observatory Project Heliospheric and Magnetic Imager (HMI) investigation, a 25-year cost-no-fee contract (2002-2027) under full and open competition. The highest-conviction signal is neutral (4/10 strength), reflecting stable but low outlays of $25,928,889 against a base + options value of $186,336,824. Dominant theme is sustained NASA commitment to heliophysics R&D via academic partners. Key risk/watch item: monitor outlay progression beyond $25.9M and performance toward the 2027-09-30 end date amid uneven spending.

Biotech Small-Cap Approvals — April 03, 2026

The FDA approved 7 'Other' products from March 27-31, 2026 (captured in the April 03 period), featuring 0 NMEs, 0 biosimilars, and 0 label expansions, with all signals rated neutral due to generic/ANDA or standard original approvals lacking premium designations. No dominant therapeutic area theme is evident, as indications remain unspecified across the board. Highest-conviction signal is TEVA PHARMACEUTICALS, INC.'s original BLA 761385 approval (materiality 4/10), a modest portfolio addition for the sponsor with low pricing power and no exclusivity. Key risk/watch item is negligible commercial differentiation in crowded generic markets, with post-approval launches as the sole near-term catalysts.

7 total filings

NME Blockbuster Approvals — April 03, 2026

The FDA approval period of April 3 to April 3, 2026, featured 1 other approval (0 NMEs, 0 biosimilars, 0 label expansions), centered on ELI LILLY AND CO's Unknown under Priority Review. No dominant therapeutic area theme is evident due to undisclosed details. The highest-conviction signal is ELI LILLY AND CO's Unknown NME approval, a bullish event (strength 8/10, materiality 8/10) signaling pipeline execution and potential commercial upside in the NME Blockbuster Approvals stream. Priority Review designation highlights FDA recognition of significant benefit. Key risk/watch item: Limited visibility into peak sales, exclusivity, pricing, and market position (all NOT_DISCLOSED), warranting post-approval commercialization monitoring.

Big Pharma Approvals — April 03, 2026

This period features 4 Other approvals (0 NME, 0 biosimilar, 0 label expansion), with a focus on rare disease assets underscored by Orphan Drug designations. Vertex Pharmaceuticals dominates with two Priority Review supplemental NDA approvals for TRIKAFTA (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR), signaling label enhancements in cystic fibrosis and reinforcing franchise strength. Highest-conviction signal is Eli Lilly and Co's NME approval for Unknown under Priority Review, a bullish execution milestone with potential 5-year exclusivity despite undisclosed commercial details. Biogen Inc's Nusinersen Sodium approval is neutral with limited data. Key risk/watch item: Uncertain label details and post-approval uptake for Vertex supplements; full commercial profile for Lilly's Unknown remains NOT_DISCLOSED.

4 total filings

Orphan Drug Approvals — April 03, 2026

This period's 6 Orphan Drug approvals consist of 0 NMEs, 0 biosimilars, 0 label expansions, and 6 other approvals, with 3 bullish, 0 bearish, and 3 neutral signals. Vertex Pharms Inc dominates with two Priority Review supplemental approvals for TRIKAFTA (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR), signaling strong label enhancement potential in orphan indications and reinforcing its franchise execution. Acadia Pharms Inc's TROFINETIDE supplemental approval adds a moderate bullish catalyst via Priority Review and Orphan exclusivity. No dominant therapeutic area theme emerges from available data; key watch item is post-approval label details and uptake for Vertex and Acadia amid unknown indication specifics.

6 total filings

New Drug Approvals (Original) — April 03, 2026

This week's 8 FDA approvals under New Drug Approvals (Original) stream comprise 0 NMEs, 0 biosimilars, 0 label expansions, and 8 others, dominated by generic ANDA entries and standard original NDAs/BLAs with neutral investment implications due to lack of premium designations and unspecified therapeutic areas. No dominant therapeutic area theme emerges as indications are largely not specified. Highest-conviction signal is Eli Lilly and Co's Unknown NME approval under Priority Review, indicating strong unmet need and potential 5-year exclusivity as a first-in-class commercial catalyst. Key risk/watch item is generic erosion from multiple ANDA approvals (e.g., MESALAMINE by KLM Labs Pvt, BENZONATATE by Marksans Pharma), though limited by unknown market sizes.

8 total filings

New Federal Contractors — April 03, 2026

These five new federal contracts total $2,789,953,840 in obligations, entirely civilian with zero defense-related awards, highlighting robust non-DOD spending. Dominant themes include a massive $2.01B Department of Energy award to WASHINGTON TRU SOLUTIONS LLC and Department of Education commitments to student loan servicing via NELNET SERVICING LLC ($200.3M) and MAXIMUS EDUCATION LLC ($164.8M). Highest-conviction signal is the bullish $200.3M NELNET SERVICING LLC award (strength 8/10, materiality 9/10) under full and open competition for future revenue starting 2026-04-01. CGI FEDERAL INC. secures two awards totaling $417M across HHS and State for IT services. Key risk is zero outlays to date on three high-materiality Education and DOE contracts, with dependency on options exercise for full value realization.

5 total filings

Significant Contract Modifications ($10M+) — April 03, 2026

Five significant civilian contract modifications totaling $2,789,953,840 (0/5 defense-related) highlight steady federal IT and financial services spending, led by Washington Tru Solutions LLC's massive $2.01B Department of Energy award and Department of Education's $365M in student loan servicing to Nelnet Servicing LLC ($200.3M) and Maximus Education LLC ($164.8M). The highest-conviction signal is bullish for Nelnet Servicing's $200.3M award (strength 8/10, materiality 9/10), representing a future revenue stream starting April 2026 under full and open competition. CGI Federal Inc. captures $417M across HHS ($261.9M neutral Medicare IT) and State Department ($155.1M bullish consular IT). Dominant theme is civilian education financial services growth. Key risk: high pricing risk on fixed-price structures for CGI HHS and Maximus Education, with options exercise critical to unlocking full ceilings over $650M combined.

5 total filings